Escitalopram

Sarah Aronson, Pedro Delgado

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability. Escitalopram is the S-enantiomer of the racemic SSRI citalopram. It has been proposed that the S-enantiomer of citalopram is the isomer that holds antidepressant efficacy, and that the R-enantiomer is clinically inactive; preclinical and clinical data support this. Based on in vitro radioligand binding data, escitalopram is the most selective SSRI available. Hypotheses that escitalopram has a more rapid onset of action or fewer adverse effects than citalopram have not yet been fully documented in published studies, although its profile is at least comparable to citalopram. Escitalopram is more effective than placebo in the treatment of major depression and as effective as other SSRIs, including citalopram. Comparable to other SSRIs, it is well tolerated, safe in overdose and has a low incidence of adverse effects or drug interactions.

Original languageEnglish (US)
Pages (from-to)121-131
Number of pages11
JournalDrugs of Today
Volume40
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Citalopram
Serotonin Uptake Inhibitors
United States Food and Drug Administration
Drug Interactions
Antidepressive Agents
Therapeutics
Placebos

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Aronson, S., & Delgado, P. (2004). Escitalopram. Drugs of Today, 40(2), 121-131. https://doi.org/10.1358/dot.2004.40.2.799424

Escitalopram. / Aronson, Sarah; Delgado, Pedro.

In: Drugs of Today, Vol. 40, No. 2, 02.2004, p. 121-131.

Research output: Contribution to journalArticle

Aronson, S & Delgado, P 2004, 'Escitalopram', Drugs of Today, vol. 40, no. 2, pp. 121-131. https://doi.org/10.1358/dot.2004.40.2.799424
Aronson S, Delgado P. Escitalopram. Drugs of Today. 2004 Feb;40(2):121-131. https://doi.org/10.1358/dot.2004.40.2.799424
Aronson, Sarah ; Delgado, Pedro. / Escitalopram. In: Drugs of Today. 2004 ; Vol. 40, No. 2. pp. 121-131.
@article{69493677f2314151a8657f92b0e87b00,
title = "Escitalopram",
abstract = "Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability. Escitalopram is the S-enantiomer of the racemic SSRI citalopram. It has been proposed that the S-enantiomer of citalopram is the isomer that holds antidepressant efficacy, and that the R-enantiomer is clinically inactive; preclinical and clinical data support this. Based on in vitro radioligand binding data, escitalopram is the most selective SSRI available. Hypotheses that escitalopram has a more rapid onset of action or fewer adverse effects than citalopram have not yet been fully documented in published studies, although its profile is at least comparable to citalopram. Escitalopram is more effective than placebo in the treatment of major depression and as effective as other SSRIs, including citalopram. Comparable to other SSRIs, it is well tolerated, safe in overdose and has a low incidence of adverse effects or drug interactions.",
author = "Sarah Aronson and Pedro Delgado",
year = "2004",
month = "2",
doi = "10.1358/dot.2004.40.2.799424",
language = "English (US)",
volume = "40",
pages = "121--131",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Escitalopram

AU - Aronson, Sarah

AU - Delgado, Pedro

PY - 2004/2

Y1 - 2004/2

N2 - Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability. Escitalopram is the S-enantiomer of the racemic SSRI citalopram. It has been proposed that the S-enantiomer of citalopram is the isomer that holds antidepressant efficacy, and that the R-enantiomer is clinically inactive; preclinical and clinical data support this. Based on in vitro radioligand binding data, escitalopram is the most selective SSRI available. Hypotheses that escitalopram has a more rapid onset of action or fewer adverse effects than citalopram have not yet been fully documented in published studies, although its profile is at least comparable to citalopram. Escitalopram is more effective than placebo in the treatment of major depression and as effective as other SSRIs, including citalopram. Comparable to other SSRIs, it is well tolerated, safe in overdose and has a low incidence of adverse effects or drug interactions.

AB - Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability. Escitalopram is the S-enantiomer of the racemic SSRI citalopram. It has been proposed that the S-enantiomer of citalopram is the isomer that holds antidepressant efficacy, and that the R-enantiomer is clinically inactive; preclinical and clinical data support this. Based on in vitro radioligand binding data, escitalopram is the most selective SSRI available. Hypotheses that escitalopram has a more rapid onset of action or fewer adverse effects than citalopram have not yet been fully documented in published studies, although its profile is at least comparable to citalopram. Escitalopram is more effective than placebo in the treatment of major depression and as effective as other SSRIs, including citalopram. Comparable to other SSRIs, it is well tolerated, safe in overdose and has a low incidence of adverse effects or drug interactions.

UR - http://www.scopus.com/inward/record.url?scp=1642361461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642361461&partnerID=8YFLogxK

U2 - 10.1358/dot.2004.40.2.799424

DO - 10.1358/dot.2004.40.2.799424

M3 - Article

C2 - 15045034

AN - SCOPUS:1642361461

VL - 40

SP - 121

EP - 131

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2

ER -